Get the Stockscreener App
0.3248
4.22%
-0.0143
Indaptus Therapeutics Inc stock is traded at $0.3248, with a volume of 142.25K.
It is down -4.22% in the last 24 hours and down -26.18% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$0.3391
Open:
$0.3289
24h Volume:
142.25K
Relative Volume:
0.21
Market Cap:
$5.50M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.1765
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-5.39%
1M Performance:
-26.18%
6M Performance:
-67.52%
1Y Performance:
-86.69%
1-Day Range:
$0.31
$0.3429
1-Week Range:
$0.31
$0.36
52-Week Range:
$0.31
$2.70
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.3248 | 5.50M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics (INDP) Secures $2.3M Through Convertible N - GuruFocus
Indaptus Therapeutics raises $2.3 million through convertible notes By Investing.com - Investing.com South Africa
Indaptus Therapeutics Announces Sale Of $2.3 Million In Private Placement Of Convertible Notes And Warrants - marketscreener.com
Indaptus Therapeutics Completes $2.3M Private Placement - TipRanks
Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round - Nasdaq
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - The Manila Times
Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum - The Manila Times
Clinical-Stage Biotech Indaptus Raises $2.3M from Healthcare Investor to Advance Cancer Treatment Trials - Stock Titan
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Estrella's $3.35M Funding Accelerates Novel T-Cell Therapy Trial for Non-Hodgkin's Lymphoma - Stock Titan
INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com India
Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
BNY Mellon Credit Fund's Last Distribution: $2.00 Payout Coming Before August Liquidation - Stock Titan
Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus
INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus
Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView
Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView
Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times
Loar Holdings Q1 2025 Earnings Call: How to Join the May 13 Investor Presentation - Stock Titan
Sandisk Key Q3 Financial Results: How to Access the May 7 Earnings Call - Stock Titan
Healthcare Giant Concentra's $55M Pivot Deal Adds 200 Workplace Clinics Across 40 States - Stock Titan
BeiGene Earnings Preview: Q1 Results Coming May 7 as Company Transforms to BeOne Medicines - Stock Titan
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World
Claritev Earnings Preview: Q1 2025 Results Coming May 8What to Watch - Stock Titan
Fortune 500 Retail Giant QVC Group Sets Stage for Crucial Q1 2025 Earnings Reveal - Stock Titan
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan
$1 Million Winner: Berkshire Employee Nails 31 of 32 March Madness Picks - Stock Titan
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com
Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India
Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan
Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia
Indaptus tests new cancer therapy combination - Investing.com India
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):